Wolfe Research has recently initiated Zimmer Biomet Holdings Inc (ZBH) stock to Peer Perform rating, as announced on September 10, 2024, according to Finviz. Earlier, on July 1, 2024, Piper Sandler had reduced the stock from a Overweight to Neutral, setting a price target of $115 for ZBH stock. Goldman also initiated Neutral rating with a price target of $129. Additionally, Argus raised Buy rating on May 21, 2024, with a target price of $150. Evercore ISI analysts, in their report published on January 4, 2024, also reduced rating and set a price target of $135 for Zimmer Biomet Holdings Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Zimmer Biomet Holdings Inc (ZBH) Stock Trading Recap
On Thursday, Zimmer Biomet Holdings Inc (ZBH) stock saw a decline, ending the day at $106.92 which represents a decrease of $-2.89 or -2.63% from the prior close of $109.81. The stock opened at $109.7 and touched a low of $106.59 during the day, reaching a high of $109.7. The volume of shares traded was 2.10 million exceeding the average volume of 1.48 million.
ZBH Stock Performance and Moving Averages
In recent trading, Zimmer Biomet Holdings Inc (ZBH) stock price has shown some volatility, fluctuating 2.81% over the last five trades and 1.16% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -9.74%, and it has plunged by -3.12% in the previous three months. Currently, ZBH is trading at 2.35%, -0.14%, and -7.42% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, ZBH, a Healthcare sector stock, is trading -20.15% below its 52-week high but remains 5.37% above its 52-week low. The Average True Range (ATR) (14 days) of 2.21 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Zimmer Biomet Holdings Inc’s Profitability and Valuation Ratios
Zimmer Biomet Holdings Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 18.35% and a profit margin of 14.27%, with a gross margin of -9.74%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Zimmer Biomet Holdings Inc’s market capitalization stands at $21.77 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 20.36, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 12.47. Additionally, the Price-to-Sales Ratio is 2.87, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 1.72, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.14% of Zimmer Biomet Holdings Inc (ZBH)’s shares, while financial institutions hold 93.04%.
Notable insider trades include Yi Sang, Group President, Asia Pacific at Zimmer Biomet Holdings Inc (ZBH), who sold 12857 shares on May 31 ’24, at $114.69 each, totaling $1.47 million. On Mar 07 ’24, Yi Sang, Group President, Asia Pacific, sold 1705 shares for $126.86 each, amounting to $0.22 million. Additionally, on Feb 22 ’24, Phipps Chad F sold 26156 shares at $128.62 each, generating $3.36 million.
